Go to Health Care Provider version
| Diagnosis | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) | Study Status | Open |
| Phase | I/II |
| Age | 18 Years and older | Randomisation | NO |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | Drug: CFI-400945 (oral)
Arm 2A only: Azacitidine (IV)
|
| Last Posted Update | 2024-04-09 |
| ClinicalTrials.gov # | NCT04730258 |
International Sponsor
Treadwell Therapeutics, IncPrincipal Investigators for Canadian Sites
Princess Margaret Cancer CentreCentres
Study Description
The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.
Inclusion Criteria
- Patients must be >18 years of age
- Patients must have a qualifying diagnosis of Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) that has come back or not responded to other treatment
- Have acceptable laboratory screening results within certain limits
- Be able to carry out light daily work with little/no restriction
Other inclusion and exclusion criteria may apply and will be discussed with you by the study team
